31 August 2018
Visiongain’s study predicts expansion in the bioinformatics market Report will continue until 2026, especially in the genomics sector, which will remain dominant. The chemoinformatics and drug discovery sector will have the highest revenue growth rate during this period, as the use of bioinformatics in personalised medicine increases. In 2015, the genomics submarket formed the most lucrative part of that industry, accounting for 48.6% of the overall world market. As the bioinformatics market grows, this segment will continue to dominate.
The report’s author said: “The bioinformatics market has strong potential, with many innovative software platforms that can offer analysis of not only genomic data but proteomic, transcriptomic and chemoinformatic data. With so many sources of data, a company that can offer integrated analysis and interpretation will have a competitive edge. Researchers will also be looking to bioinformatics companies to provide security and flexibility such as cloud-based bioinformatics to facilitate collaborations and enable data access from anywhere. An important restraint on growth of the market will be a shortage of trained expertise; over our forecast period the success of the market will depend on remedying this deficit. The bioinformatics market will continue to expand, bolstered by governmental investment and lower costs of sequencing, as the trend towards personalised medicine ensures that demand stays strong.”
Visiongain’s new investigation shows bioinformatic revenue predictions to 2026 at overall world market, submarket and regional level. First it forecasts the following segments of the bioinformatics market to 2026:
• Genomics • Metabolomics • Proteomics • Transcriptomics • Chemoinformatics and drug discovery • Other applications.
That work also analyses leading national markets for those informatics tools, providing revenue forecasts to 2026 for these countries and regions:
• United States • European Union • Japan • China • India • Rest of the world.
In addition visiongain’s survey examines leading bioinformatic companies. That study discusses mergers and acquisitions, collaborations and developments, also showing a research interview. The report highlights organisations such as these:
• QIAGEN • Illumina • Thermo Fisher Scientific • 3rd Millennium • DNASTAR • DNAnexus • Compugen.
Bioinformatics Market Analysis, Developments and Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research, manufacturing and selling. Each year new and updated studies appear.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market